Today we received three groups of anemia syndrome companies. All three companies have continued losses and insufficient income, and each has its own characteristics. Company B1 has an estimated revenue of 100 million yuan, a loss of 7 million yuan, available funds of 150 million

received three groups of companies with anemia syndrome today. All three companies have continued losses and insufficient income, and each has its own characteristics. Company

b1 has an estimated revenue of 100 million yuan, a loss of 7 million yuan, available funds of 150 million yuan, and no interest-bearing liabilities. . Mainly engaged in Chinese patent medicines, due to the impact of centralized procurement, its main business has been unable to recover;

b2 company, with an estimated revenue of 220 million yuan, has suffered huge losses, has no available funds, and its net assets are close to 0. Mainly engaged in system integration of video technology, with no core technology and a certain big B customer base;

b3 company, revenue is expected to be 70 million yuan, huge losses, asset realization value is estimated to be 200 million yuan, no funds available within three months, long-term Borrow 70 million yuan. The main business is complex, with new energy, new media, and car rental each accounting for 30%, and hardware trading accounting for 10%.

Before the National Nine Articles came out, the three companies thought that they were safe. After the National Article 9, (1) there was only a short period of half a year for blood transfusions, and (2) what is even more terrible is that regulatory agencies have greatly tightened the operating standards for blood transfusions. What could have been done by county hospitals is now at a loss for top tertiary hospitals.

Currently, in response to the shelling behavior of surprise blood transfusions (income and profits), regulatory agencies are actually implementing unlimited veto power through window guidance (strict review of review opinions) and high-frequency inquiries. Concentrated on four aspects,

main business caliber

The income and net profit that can be included in the consolidated calculation this year must be the main business caliber. (1) If it is not a product/service with original sales records, the rationality of the development or acquisition of the product must be proven etc., (2) If the original business/products are relatively scattered, the classification of the new business/product must account for more than 20% of the original classification.

Time caliber

The income and profits generated by the acquisition or establishment of a new company must exceed 12 months before there is an opportunity to consolidate the statement.

Reasonability

Three truths, (1) real products, (2) real customers, please note that the revenue must be confirmed by the purchasing/consuming terminal, and the intermediaries who stock up on goods will definitely be strictly investigated, and the same goes for overseas sales, (3) Real channels.

Sustainability

To prove the sustainability of new business for at least the next two years, one-time trading business is almost never recognized. There is nothing we can do about

b2 company. We suggest that we first transfer the control rights to an expert for free. The consultation fee is RMB 10,000 today.

Shell protection hotline: 18600021395 (same number on WeChat)

Copyright statement: The copyright of this article belongs to "Kunyu Business Observer". If you need to reprint, please leave a message after the article. If there are copyright issues involved, please contact us in time to discuss the deletion process.

Email: 975163774@qq.com

Business WeChat: qingcaijinggzh